Journal
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
Volume 70, Issue 11, Pages 3096-3099Publisher
OXFORD UNIV PRESS
DOI: 10.1093/jac/dkv208
Keywords
-
Funding
- Bristol-Myers Squibb
Ask authors/readers for more resources
Background: Atazanavir without ritonavir, despite efficacy and tolerability, shows low plasma concentrations that warrant optimization. Methods: In a randomized, controlled, pilot trial, stable HIV-positive patients on atazanavir/ritonavir (with tenofovir/emtricitabine) were switched to atazanavir. In the standard-dose arm, atazanavir was administered as 400 mg once daily, while according to patients' genetics (PXR, ABCB1 and SLCO1B1), in the pharmacogenetic arm: patients with unfavourable genotypes received 200 mg of atazanavir twice daily. EudraCT number: 2009-014216-35. Results: Eighty patients were enrolled with balanced baseline characteristics. The average atazanavir exposure was 253 ng/mL (150-542) in the pharmacogenetic arm versus 111 ng/mL (64-190) in the standard-dose arm (P<0.001); 28 patients in the pharmacogenetic arm (75.7%) had atazanavir exposure >150 ng/mL versus 14 patients (38.9%) in the standard-dose arm (P = 0.001). Immunovirological and laboratory parameters had a favourable outcome throughout the study with non-significant differences between study arms. Conclusions: Atazanavir plasma exposure is higher when the schedule is chosen according to the patient's genetic profile.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available